Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Exp Eye Res. 2019 Sep 11;188:107798. doi: 10.1016/j.exer.2019.107798

Figure 3. Peptide inhibition of CNV.

Figure 3.

(A) TSP1-derived and PEDF-derived test peptide sequences are shown in relation to original protein sequence. Benchmark anti-angiogenic TSP-1 mimetic peptide (ABT-898): Ac-GV-d-alloIle-Ser-Q-I-R-Pro-ethylamide has been shown to inhibit laser-induced mouse CNV (Wang et al., 2012). Substituting N-terminal adipic acid as a half-amide in place of the N-acetyl group gave TSP-868, also displaying anti-CNV activity, with potential capacity to form an adipic half-ester prodrug. (B) TSP-868 (2μL, 2 mM) was compared against balanced salts vehicle at different times of IVT injection where day 0 is the day of laser treatment. CNV mitigation by peptide TSP-868 was significant when 4 ng in 2 μL PBS was IVT-injected on the day of laser, with effect enhanced by injecting at day −2 (not shown) or day −5 before laser treatment. No isignificant inhibition of CNV was evident with injection at day −10. (C) Peptides PEDF 335 and PEDF 336 were IVT injected (2μL, 2 mM) 2 days prior to laser treatment. PEDF-335 and PEDF-336 IVT injection at day −2 significantly decreased CNV by 40–50%, similar inhibition was obtained with injection on day −5 (not shown). In all cases eyes were harvested for CNV analysis at day +14.